Blood markers in newly diagnosed acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study measures two simple blood markers (SII and CAR) in people newly diagnosed with acute lymphoblastic leukemia (ALL) who haven't started treatment yet. The goal is to see if these markers can help guide care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be newly diagnosed with acute lymphoblastic leukemia (ALL)
- Must not have received any treatment for ALL yet
- No other blood disorders besides ALL
- No history of other cancers or relapsed ALL
- Not currently on chemotherapy or radiation therapy
- No signs of infection or autoimmune disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help track how well treatment is working in children with leukemia. It may help doctors understand the disease better and guide future care.
This trial studies how different blood cancers and early (pre-cancer) blood conditions work, using tumor/blood tissue samples. It may help researchers learn more about disease biology for future treatments, with little to no extra risk if samples come from routine care.
This study looks at simple blood test results from people newly diagnosed with acute lymphoblastic leukemia (ALL) to see if certain markers help understand the disease better.
This trial looks at blood types (ABO and Rh) in people newly diagnosed with acute leukemia. It may help doctors understand if certain blood types are more common in these patients.
This study looks at two natural proteins (IL-17A and IL-10) in the blood of people newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) in South Egypt. It aims to see if these proteins relate to how active the leukemia is, which could help doctors understand the disease better.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.